Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken.
Watch this short video to learn why!

Benchmark: Opioid Treatment Program Regulations Update

Take this benchmark to assess how much you would benefit from taking the course on Medications for the Treatment of Opioid Use Disorder (MOUD). In a few minutes, you’ll gauge your grasp of why the HHS final rule matters, what it changes in OTP accreditation and certification, how treatment standards are shifting toward patient-centered care, and how the removal of the DATA Waiver affects workflows and access. The prompts focus on practical trade-offs (access vs diversion risk, flexibility vs compliance), operational impacts (protocol updates, staffing, CQI, supervision), and equity considerations (who benefits or may face new barriers). If the questions feel hard to judge or you’re unsure how to balance these factors, you’ll likely benefit from the course. Completing the course will help you confidently apply the rule, align with SAMHSA and DEA expectations, strengthen diversion control, and expand safe, equitable access to MOUD.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.

Federal Register Title
This benchmark will help determine your readiness for: Federal Register Document titled Medications for the Treatment of Opioid Use Disorder. Document Number: 2024-01693

Buy this Course
FR-24-679-1

About Benchmarks:

Are you ready for this regulation? Use this benchmark to find out.

Each benchmark is build directly for the federal regulation.  They reflect the learning objectives of the related course.

The benchmark is not a “trivia test” – they help you evaluate your readiness to apply the new regulation.

Contact us for more information and/or personalized benchmarks for your specific organization/industry.

Benchmark: Opioid Treatment Program Regulations Update

Take this benchmark to assess how much you would benefit from taking the course on Medications for the Treatment of Opioid Use Disorder (MOUD). In a few minutes, you’ll gauge your grasp of why the HHS final rule matters, what it changes in OTP accreditation and certification, how treatment standards are shifting toward patient-centered care, and how the removal of the DATA Waiver affects workflows and access. The prompts focus on practical trade-offs (access vs diversion risk, flexibility vs compliance), operational impacts (protocol updates, staffing, CQI, supervision), and equity considerations (who benefits or may face new barriers). If the questions feel hard to judge or you’re unsure how to balance these factors, you’ll likely benefit from the course. Completing the course will help you confidently apply the rule, align with SAMHSA and DEA expectations, strengthen diversion control, and expand safe, equitable access to MOUD.

NOTE: Unless otherwise indicated, all Benchmarks are free of charge!

Federal Register Title
This benchmark will help determine your readiness for: Federal Register Document titled Medications for the Treatment of Opioid Use Disorder. Document Number: 2024-01693

Buy this Course
FR-24-679-1

Replenish your Studio Course Advisor Unit balance here . Please contact frsales@courseavenue.com if you need to purchase more. Talk to use about an Enterprise License to see if that is right for you!

Benchmark: Opioid Treatment Program Regulations Update

Federal Register Title
This benchmark will help determine your readiness for: Federal Register Document titled Medications for the Treatment of Opioid Use Disorder. Document Number: 2024-01693

Buy this Course
FR-24-679-1

Take this benchmark to assess how much you would benefit from taking the course on Medications for the Treatment of Opioid Use Disorder (MOUD). In a few minutes, you’ll gauge your grasp of why the HHS final rule matters, what it changes in OTP accreditation and certification, how treatment standards are shifting toward patient-centered care, and how the removal of the DATA Waiver affects workflows and access. The prompts focus on practical trade-offs (access vs diversion risk, flexibility vs compliance), operational impacts (protocol updates, staffing, CQI, supervision), and equity considerations (who benefits or may face new barriers). If the questions feel hard to judge or you’re unsure how to balance these factors, you’ll likely benefit from the course. Completing the course will help you confidently apply the rule, align with SAMHSA and DEA expectations, strengthen diversion control, and expand safe, equitable access to MOUD.

Related products